| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
| 2 | Hypoxia signalling in cancer and approaches to enforce tumour regression | Nature | 2006 | 1,525 |
| 3 | Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value | PLoS Medicine | 2013 | 1,064 |
| 4 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2014 | 595 |
| 5 | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2013 | 586 |
| 6 | Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force | European Journal of Neurology | 2010 | 428 |
| 7 | Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function | Oncogene | 2003 | 423 |
| 8 | Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | Annals of Oncology | 2018 | 387 |
| 9 | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial | Lancet Oncology, The | 2017 | 372 |
| 10 | Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial | European Urology | 2016 | 355 |
| 11 | Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) | Lancet Oncology, The | 2014 | 351 |
| 12 | Management of hypertension in angiogenesis inhibitor-treated patients | Annals of Oncology | 2009 | 305 |
| 13 | Prognostic factors in 1038 women with metastatic breast cancer | Annals of Oncology | 2008 | 301 |
| 14 | Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis | PLoS Medicine | 2016 | 300 |
| 15 | Compared Performance of High-Sensitivity Cameras Dedicated to Myocardial Perfusion SPECT: A Comprehensive Analysis of Phantom and Human Images | Journal of Nuclear Medicine | 2012 | 226 |
| 16 | The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale | Haematologica | 2014 | 225 |
| 17 | Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study | Lancet Oncology, The | 2019 | 222 |
| 18 | MAP kinases and hypoxia in the control of VEGF expression | Cancer and Metastasis Reviews | 2000 | 204 |
| 19 | HIF‐1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome | International Journal of Cancer | 2007 | 202 |
| 20 | Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial | Lancet Oncology, The | 2016 | 200 |
| 21 | Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study | Journal of Clinical Oncology | 2019 | 184 |
| 22 | Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2020 | 182 |
| 23 | Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study | Annals of Oncology | 2018 | 150 |
| 24 | Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Delivered on 24 October 2002 at the 28th FEBS Meeting in Istanbul | FEBS Journal | 2003 | 149 |
| 25 | Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) | British Journal of Cancer | 2002 | 143 |
| 26 | Oncoplastic surgery for breast cancer based on tumour location and a quadrant-per-quadrant atlas | British Journal of Surgery | 2012 | 141 |
| 27 | Radiation-enhanced cell migration/invasion process: A review | Critical Reviews in Oncology/Hematology | 2014 | 140 |
| 28 | Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis | Nature Medicine | 2011 | 137 |
| 29 | Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial | Lancet Oncology, The | 2016 | 135 |
| 30 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | Cancer Treatment Reviews | 2018 | 134 |
| 31 | A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial | Journal of Thoracic Oncology | 2019 | 132 |
| 32 | French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC) | International Journal of Radiation Oncology Biology Physics | 2006 | 124 |
| 33 | Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study | Lancet Oncology, The | 2019 | 123 |
| 34 | Extracellular Signal-Regulated Kinases Phosphorylate Mitogen-Activated Protein Kinase Phosphatase 3/DUSP6 at Serines 159 and 197, Two Sites Critical for Its Proteasomal Degradation | Molecular and Cellular Biology | 2005 | 119 |
| 35 | Treatment strategies for breast cancer brain metastases | British Journal of Cancer | 2021 | 117 |
| 36 | ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost – GEC-ESTRO Breast Cancer Working Group practical recommendations | Radiotherapy and Oncology | 2018 | 115 |
| 37 | Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck | European Journal of Cancer | 2019 | 115 |
| 38 | Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors | Annals of Oncology | 2021 | 115 |
| 39 | Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b | Oncogene | 2004 | 113 |
| 40 | Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort | British Journal of Cancer | 2019 | 113 |
| 41 | Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery | Radiotherapy and Oncology | 2015 | 111 |
| 42 | Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations | Annals of Oncology | 2020 | 105 |
| 43 | Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer | British Journal of Cancer | 2002 | 104 |
| 44 | Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model | European Urology | 2015 | 102 |
| 45 | Anal canal carcinoma: Early-stage tumors ≤10 mm (T1 or Tis): Therapeutic options and original pattern of local failure after radiotherapy | International Journal of Radiation Oncology Biology Physics | 2005 | 101 |
| 46 | The magic of the hypoxia-signaling cascade | Cellular and Molecular Life Sciences | 2008 | 101 |
| 47 | Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity | Annals of Oncology | 2007 | 100 |
| 48 | Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies | Annals of Oncology | 2015 | 99 |
| 49 | Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study | Annals of Oncology | 2015 | 98 |
| 50 | Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells | Blood | 2006 | 97 |
